Kodiak Sciences Inc
KOD
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.30 | 5.00 | -0.06% |
| CAC 40 | 7,793.98 | 35.31 | -0.45% |
| DAX 40 | 24,042.32 | 212.99 | -0.88% |
| Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
| FTSE 100 | 8,973.66 | 32.54 | 0.36% |
| HKSE | 24,203.32 | 63.75 | 0.26% |
| NASDAQ | 20,585.53 | 45.14 | -0.22% |
| Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
| NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
| S&P 500 | 6,259.75 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
| SSE Composite Index | 3,519.65 | 9.47 | 0.27% |